TY - JOUR
T1 - Direct and indirect effects on child neurocognitive development when maternal cancer is diagnosed during pregnancy
T2 - What do we know so far?
AU - van Assche, Indra A.
AU - Lemiere, Jurgen
AU - Amant, Frédéric
AU - van Calsteren, Kristel
N1 - Funding Information: Indra A. Van Assche is funded by Kom op Tegen Kanker (KOTK) as PhD researcher under the research project ‘Cancer Treatment During Pregnancy’, grant number ZKD6005 . KOTK is an independent non-profit organisation and non-governmental organisation for cancer research, education, and support. KOTK had no involvement in the idea, writing, editing of, or decision to submit this review. Publisher Copyright: © 2022 Elsevier B.V.
PY - 2022/11/1
Y1 - 2022/11/1
N2 - Cancer during pregnancy threatens the lives of mother and foetus and its incidence is rising, making it an emerging medical challenge. Evidence on the direct impact of cancer therapies on neonatal outcomes resulted in general guidelines for maternal treatment that safeguards foetal development. Less focus has been placed on indirect factors, in pre- and postnatal periods, that may exert long-term impacts specifically on child neurocognition. Foetal development, in the context of maternal cancer during pregnancy, may be influenced directly by exposure to cancer diagnostics and (co-)treatment, or indirectly through maternal inflammation, malnutrition, hormonal fluctuations, prematurity, and psycho-biological stress. Maternal stress and insecure mother-infant bonding related to postpartum cancer treatment may further impact child cognitive-behavioural development. Understanding the independent and synergistic effects of the factors impacting neurocognitive development creates the opportunity to intervene during the oncological treatment to improve the child's long-term outcome, both by medical and psychosocial care and support.
AB - Cancer during pregnancy threatens the lives of mother and foetus and its incidence is rising, making it an emerging medical challenge. Evidence on the direct impact of cancer therapies on neonatal outcomes resulted in general guidelines for maternal treatment that safeguards foetal development. Less focus has been placed on indirect factors, in pre- and postnatal periods, that may exert long-term impacts specifically on child neurocognition. Foetal development, in the context of maternal cancer during pregnancy, may be influenced directly by exposure to cancer diagnostics and (co-)treatment, or indirectly through maternal inflammation, malnutrition, hormonal fluctuations, prematurity, and psycho-biological stress. Maternal stress and insecure mother-infant bonding related to postpartum cancer treatment may further impact child cognitive-behavioural development. Understanding the independent and synergistic effects of the factors impacting neurocognitive development creates the opportunity to intervene during the oncological treatment to improve the child's long-term outcome, both by medical and psychosocial care and support.
KW - Cancer in pregnancy
KW - Cancer treatment impact on neonatal outcomes
KW - Foetal programming
KW - Indirect effects of cancer treatment
KW - Insecure mother-infant bonding
KW - Neurocognitive development
KW - Postnatal cancer treatment
KW - Prenatal cancer treatment
UR - http://www.scopus.com/inward/record.url?scp=85138761199&partnerID=8YFLogxK
U2 - https://doi.org/10.1016/j.critrevonc.2022.103824
DO - https://doi.org/10.1016/j.critrevonc.2022.103824
M3 - Review article
C2 - 36174901
SN - 1040-8428
VL - 179
JO - Critical Reviews in Oncology/Hematology
JF - Critical Reviews in Oncology/Hematology
M1 - 103824
ER -